临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2009年
4期
296-297,302
,共3页
朱宛平%梁涛%伍帮荣%赵守云
硃宛平%樑濤%伍幫榮%趙守雲
주완평%량도%오방영%조수운
脑血管病所致精神障碍%奎硫平%奋乃静%临床疗效%不良反应%简明精神病量表%简明智能状况检查量表%副反应量表
腦血管病所緻精神障礙%奎硫平%奮迺靜%臨床療效%不良反應%簡明精神病量錶%簡明智能狀況檢查量錶%副反應量錶
뇌혈관병소치정신장애%규류평%강내정%림상료효%불량반응%간명정신병량표%간명지능상황검사량표%부반응량표
Mental disorders due to cerebrovascular disease%quetiapine%perphenazine%efficacy%adverse reactions%BPRS%MMSE%TESS
目的 评价奎硫平与奋乃静治疗脑血管病所致精神障碍的临床疗效和安全性. 方法 将71例脑血管病所致精神障碍患者随机分为两组,研究组30例,对照组41例,均给予神经内科常规治疗,在此基础上研究组口服奎硫平治疗,对照组口服奋乃静治疗,观察6 w.于治疗前及治疗1 w、2 w、4 w、6 w末采用简明精神病量表评定临床疗效,简明智能状况检查量表评定认知状况,副反应量表评定不良反应. 结果 治疗6 w末,研究组显效率为70%,对照组为65.9%;两组治疗2 w末起简明精神病量表评分均较治疗前有显著下降(P均＜0.01),并随着治疗时间的延续呈持续性下降,其减分率呈持续性升高;同期两组间评分及减分率比较均无显著性差异(P＞0.05).两组治疗前后简明智能状况检查量表评分虽无显著性差异(P＞0.05),但对照组减分率高于研究组.两组出现的不良反应多为轻、中度,但对照组的发生率显著高于研究组;其中活动减少、嗜睡、震颤、视物模糊、便秘以及体重增加的发生率差异有显著性(P＜0.05).结论奎硫平治疗脑血管病所致精神障碍疗效显著,与奋乃静相当,但对认知功能影响较小,不良反应较轻微,安全性高,依从性好.
目的 評價奎硫平與奮迺靜治療腦血管病所緻精神障礙的臨床療效和安全性. 方法 將71例腦血管病所緻精神障礙患者隨機分為兩組,研究組30例,對照組41例,均給予神經內科常規治療,在此基礎上研究組口服奎硫平治療,對照組口服奮迺靜治療,觀察6 w.于治療前及治療1 w、2 w、4 w、6 w末採用簡明精神病量錶評定臨床療效,簡明智能狀況檢查量錶評定認知狀況,副反應量錶評定不良反應. 結果 治療6 w末,研究組顯效率為70%,對照組為65.9%;兩組治療2 w末起簡明精神病量錶評分均較治療前有顯著下降(P均＜0.01),併隨著治療時間的延續呈持續性下降,其減分率呈持續性升高;同期兩組間評分及減分率比較均無顯著性差異(P＞0.05).兩組治療前後簡明智能狀況檢查量錶評分雖無顯著性差異(P＞0.05),但對照組減分率高于研究組.兩組齣現的不良反應多為輕、中度,但對照組的髮生率顯著高于研究組;其中活動減少、嗜睡、震顫、視物模糊、便祕以及體重增加的髮生率差異有顯著性(P＜0.05).結論奎硫平治療腦血管病所緻精神障礙療效顯著,與奮迺靜相噹,但對認知功能影響較小,不良反應較輕微,安全性高,依從性好.
목적 평개규류평여강내정치료뇌혈관병소치정신장애적림상료효화안전성. 방법 장71례뇌혈관병소치정신장애환자수궤분위량조,연구조30례,대조조41례,균급여신경내과상규치료,재차기출상연구조구복규류평치료,대조조구복강내정치료,관찰6 w.우치료전급치료1 w、2 w、4 w、6 w말채용간명정신병량표평정림상료효,간명지능상황검사량표평정인지상황,부반응량표평정불량반응. 결과 치료6 w말,연구조현효솔위70%,대조조위65.9%;량조치료2 w말기간명정신병량표평분균교치료전유현저하강(P균＜0.01),병수착치료시간적연속정지속성하강,기감분솔정지속성승고;동기량조간평분급감분솔비교균무현저성차이(P＞0.05).량조치료전후간명지능상황검사량표평분수무현저성차이(P＞0.05),단대조조감분솔고우연구조.량조출현적불량반응다위경、중도,단대조조적발생솔현저고우연구조;기중활동감소、기수、진전、시물모호、편비이급체중증가적발생솔차이유현저성(P＜0.05).결론규류평치료뇌혈관병소치정신장애료효현저,여강내정상당,단대인지공능영향교소,불량반응교경미,안전성고,의종성호.
Objective To evaluate the efficacy and safety of quetiapine vs. perphenazine in the treatment of mental disorders due to cerebrovascular disease(MDCD). Methods 71 MDCD patients were randomly divided into two groups,both groups received routine treatment of neurology department,additionally research group(n=30) took orally quetiapine and control(n=41) did perphenazine for 6 weeks.The efficacy was assessed with the Brief Psychiatric Rating Scale( BPRS),cognition status with the Mini-Mental State Examination(MMSE) and adverse reactions with the Treatment Emergent Symptom Scale(TESS) before treatment and at the end of the 1st,2nd,4th and 6th week treatment.Results At the end of the 6th week, obvious effective rate was respectively 70% in the research and 65.9% in the control;since the end of the 2nd week, the BPRS scores of both groups lowered more significantly compared with pretreatment(P<0.01) and did continously with treatment,and their score-decrement rates elevated continously;there were no significant differences in synchroniaztion inetrgroup scores and score-decrement rates(P>0.05).Although there was no significant difference in pre-and post-treatment MMSE scores of both groups(P>0.05),score-decrement rate was higher in the control than in the research group. Adverse reactions of both groups were mild to moderate,but incidences of those were significantly higher in the control than in the research group;among them,the incidence of hypoactivity, drowsiness,tremor,blurred vision,constipation and weight gain had significant difference(P<0.05). Conclusion Quetiapine has an evedent effect equivalent to perphenazine in the treatment of mental disorders due to vascular disease,but less influence on cognitive function,mild adverse reactions,higher safety and better compliance.
